ABSTRACT The molybdenum cofactor isolated from sulfite oxidase (sulfite:ferricytochrome coxidoreductase, EC 1.8.2.1) and xanthine dehydrogenase (xanthine: NAD+ oxidoreductase, EC 1.2. 1.37) in the presence ofiodine and KI (form A) has been shown to contain a pterin nucleus with an unidentified substituent in the 6 position [Johnson, J. L., Hainline, B. E. & Rajagopalan, K. V. (1980) J. Biol. Chem. 255, 1783Chem. 255, -1786. A second inactive form of the cofactor was isolated aerobically but in the absence of iodine and KI. The latter cofactor derivative (form B) is highly fluorescent, has a visible absorption band at 395 nm and, like form A, contains a phosphate group. Cleavage ofthe phosphate ester bond with alkaline phosphatase exposes a glycol function that is sensitive to periodate. Oxidation of form B with alkaline permanganate yields a highly polar compound with properties of a sulfonic acid, suggesting that the active molybdenum cofactor might contain sulfur. The sulfur-containing pterin urothione characterized by Goto et al [Goto, M., Sakurai, A., Ohta, K. & Yamakami, H. (1969) J. Biochem. 65, 611-620] had been isolated from human-urine.. The permanganate oxidation product of urothione, characterized by Goto eta! as pterin-6-carboxylic-7-sulfonic acid, is identical to that obtained from form B. Because urothione also contains a periodate-sensitive glycol substituent, a structural relationship is suggested. The finding that urine samples from patients deficient in the molybdenum cofactor are devoid of urothione demonstrates a metabolic link between the two molecules.
Previous reports from this laboratory (1) (2) (3) have documented progress towards characterization of the molybdenum cofactor present in sulfite oxidase (sulfite:ferricytochrome c oxidoreductase, EC 1.8.2.1), xanthine dehydrogenase (xanthine: NAD+ oxidoreductase, EC 1.2.1.37), and nitrate reductase (NADH) (NADH:nitrate oxidoreductase, EC 1.6.6.1). Structural studies on an oxidized, fluorescent derivative (form A) of the cofactor obtained by denaturation of the molybdoenzymes in the presence of KI and 12 have established that the cofactor contains a novel pterin (2) . Form A as isolated is a phosphate ester which can be dephosphorylated by treatment with alkaline phosphatase (3) . In this paper, we describe the oxidative modification of the cofactor to a second fluorescent species (form B). As documented below, the chemical properties ofform B are strikingly similar to those of an unusual sulfur-containing pterin isolated from human urine more than 40 years ago and termed urothione urothione (4) . The observed structural relationship between the two molecules prompted an investigation of urothione excretion in normal individuals and in molybdenum cofactor-deficient patients (5) . The finding that urothione is present in urine from normal individuals but is undetectable in the urine ofcofactor-deficient patients provides evidence that urothione is in fact the metabolic excretory product ofthe molybdenum cofactor. A possible structural basis for this metabolic relationship is presented.
MATERIALS AND METHODS
Chicken liver sulfite oxidase was purified as described (6, 7) . Sephadex G-25 and QAE-Sephadex were from Sigma, Florisil resin was from Fisher, alkaline phosphatase from chicken intestine was from Worthington, and pterin-6-carboxylic acid and isoxanthopterin were from Aldrich.
Absorption spectra were recorded on a Perkin-Elmer 575 spectrophotometer. Uncorrected fluorescence spectra were obtained with an Aminco-Bowman SPF spectrofluorometer. Fluorescent bands on columns and plates were visualized with a UVL-56 long-wavelength Blak-Ray lamp. Phosphate was quantitated by the method of Ames (8) . Alkaline phosphatase cleavage was carried out on samples at pH [8] [9] in the presence of 7.5 mM MgCl2.
Oxidation with alkaline permanganate was done by adding excess potassium permanganate to samples in 0.1 M NaOH and heating in a boiling water bath for 50 min. Ethanol was added to destroy residual permanganate, and the samples were cooled 6856
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Oxidation with periodate was carried out with 10 mM sodium metaperiodate on samples in 0.01 M acetic acid. At this concentration of periodate, the reactions for both form B (dephospho) and urothione were complete in <1 min at room temperature. The reaction mixtures were chromatographed on HPLC, and the isolated pterin derivatives were taken to dryness by rotoevaporation. The residues were dissolved in 1 ml of 0.1 M NaOH for spectral studies and then neutralized with HC1.
The periodate products were allowed to react with 0.5 ml of 2,4-dinitrophenylhydrazine (0.1% in 2 M HCI) at 100'C for 10 min (9) . The samples were chromatographed on HPLC with 40% methanol, and the isolated hydrazones were taken to dryness and then dissolved in 800 1.l of H20. NaOH (200 A.l of a 1 M solution) was added to demonstrate the orange hydrazone color.
RESULTS
Denaturation of the molybdoenzymes sulfite oxidase, xanthine dehydrogenase, or nitrate reductase with 6 M guanidine HCl in the presence of KI and I2 releases the same low molecular weight fluorescent compound (molybdenum cofactor form A), which is converted to pterin-6-carboxylic acid by alkaline permanganate oxidation (2) . Form A also was released by boiling any of these enzymes at pH 2.5 for 20 min in the presence of KI and I2. The fluorescence and absorption spectra of form A released from sulfite oxidase in this manner and purified by chromatography on Sephadex G-25 and QAE-Sephadex are shown in Fig. 1 .
When the denaturation in boiling acid (pH 2.5) was carried out in the absence of KI and I2, quite a different fluorescent species (form B) was produced. The fluorescence and absorption spectra of form B after purification on Sephadex G-25 and QAE-Sephadex are shown in Fig. 1 . The low-energy absorption band at 380 nm characteristic ofform A shifted to 395 nm in the case ofform B. with corresponding changes in the fluorescence excitation spectra. Significant differences between the two species were also evident in the UV regions ofthe absorption spectra.
Like form A (3), form B contains a terminal phosphate residue, which could be removed with alkaline phosphatase. Quantitation oforganic phosphate indicated an extinction coefficient e of 12,000 M'1cm-1 at 395 nm for form B of the cofactor. Exposure to 1 M HCl at 100°C for 1 hr converted 33% of form B to the dephosphorylated form, which we call form B (dephos-500 300 Wavelength, nm pho). Form B (dephospho) was sensitive to periodate oxidation, yielding an aldehyde derivative that produced an unstable intense orange dinitrophenylhydrazone when treated with 2,4-dinitrophenylhydrazine and subjected to alkaline conditions. The HPLC elution profiles for form B, form B (dephospho), and the periodate product of form B (dephospho) are shown in Fig.  2 .
As reported (2), treatment ofform A of the molybdenum cofactor with permanganate in alkaline solution led to the rapid appearance of pterin-6-carboxylic acid, identified by its fluorescence and absorption spectra and by its mobility on cellulose thin-layer plates in several solvents. The conversion to pterin-6-carboxylic acid provided evidence for the presence ofan alkyl substituent in the 6 position of the pterin in form A of the oxidized molybdenum cofactor. As described below, attempts to convert form B derived from the cofactor to pterin-6-carboxylic acid were without success.
Chromatography of a solution of permanganate-treated form B on a cellulose thin-layer plate with 4% sodium citrate revealed two major fluorescent products-a green-fluorescing species (product 1) with an RF of 0.84 and a purple-fluorescing species (product 2) with an RF of 0.59. Under these conditions, pterin-6-carboxylic acid appeared as a blue fluorescent band with an RF of 0.41, and isoxanthopterin migrated as a purple-fluorescing spot with an RF of 0. 28. The two fluorescent permanganate oxidation products ofform B were eluted from the cellulose with 1 M NH40H, and their fluorescent spectra were recorded. The green-fluorescing species had excitation maxima at 270 and 380 nm and an emission maximum at 470 nm. Its extremely polar character was confirmed by HPLC, and its anionic nature was established by its strong affinity for QAE-Sephadex. The purple-fluorescing species showed 345/415-nm (excitation/emission) fluorescence in ammonia, and its spectrum was indistinguishable from that ofisoxanthopterin in this solvent. However, the fluorescent spectrum of product 2 was drastically altered in acidic solvents, whereas that of isoxanthopterin remained unchanged. The spectral features and thin-layer chromatographic mobility data suggested that product 2 was an isoxanthopterin derivative with a polar, acidic substituent. The production of a 7-substituted pterin derivative from form B of the molybdenum cofactor pterin was surprising, especially because form A yielded exclusively the 6-substituted molecule.
It has been proposed from EPR (10) and x-ray absorption extended fine-structure (11) Biochemistry: Johnson and Rajagopalan cr protein, it seemed possible that some of the sulfur ligands are components of the molybdenum cofactor itself. If the cofactor were in fact a sulfur-containing pterin, the acidic species obtained by permanganate oxidation ofform B could be a sulfonic acid derivative. A search of the literature for sulfur-containing pterins focused our attention on an unusual compound of unknown function isolated from human urine in 1940 (4) and termed urothione. The complete structure of urothione was established by Goto et aL in 1969 (12) and is shown in Scheme I. According to Goto et aL (12) (12) were used, including acidification, filtration, and the first chromatography on Florisil resin. In lieu of repeated chromatography on cellulose and Florisil columns, the sample was adjusted to pH 8 with NH40H and applied to a column of QAE-Sephadex. The column was washed with H20 and then with 0.01 M acetic acid. Aliquots of each fraction were assayed for the presence of urothione by monitoring the appearance of green fluorescence (pterin-6-carboxylic-7-sulfonic acid) after boiling with alkaline permanganate. Fractions positive in the sulfonic acid assay were pooled and subjected to rotoevaporation. When the volume was reduced to about 2 ml, an orange-yellow precipitate was formed, which was collected by centrifugation and dissolved in 0.1 M NaOH. The absorption spectra in base and in acid (Fig.  3) were identical to those reported by Goto et al. (12) for urothione. The HPLC elution profile of the sample indicated that urothione was eluted with 30 ml of 20% methanol as an UVabsorbing nonfluorescent species. The minor, fluorescent contaminants eluted ahead of urothione were removed by subjecting the entire sample to HPLC. The yield ofpure urothione from 1 liter of urine was 200 jg based on an e398 nm of 11,400 M-'cm-' (13) .
Samples of urothione (70 nmol) and form B of the molybdenum cofactor (60 nmol) were boiled separately for 50 min in 0.1 M NaOH with excess KMnO4. The residual KMnO4 was destroyed with ethanol, and the samples were cooled and centrifuiged to remove the MnO2. The clear supernatant solutions were adjusted to pH 6 with HCI and chromatographed on the reverse-phase HPLC column in 20% methanol adjusted to pH 3.6 with acetic acid. Under these conditions, the permanganate product 2 was partially protonated and retarded on the column, so that the breakthrough fractions contained only the permanganate product 1. The absorption spectra ofproduct 1 from form B and from urothione in 0.1 M NaOH and 0.1 M HCI were recorded (Fig. 4 ) and found to be identical to those described by Goto et alL (12) for pterin-6-carboxylic-7-sulfonic acid.
The identity of the pterin-6-carboxylic-7-sulfonic acid isolated from urothione and that recovered from form B of the cofactor was further established by demonstrating conversion to isoxanthopterin by heating for 2 hr in 4 M HCI and to isoxanthopterin-6-carboxylic acid (permanganate product 2) by heating for 2 hr in 2 M NaOH. The spectral properties of isoxanthopterin-6-carboxylic acid reported by Matsuura et al. (14) indicated 80-90% conversion ofurothione to this compound by the procedures described.
The glycol functions present in urothione and in form B (dephospho) of the cofactor make these molecules susceptible to cleavage by periodate. The products of periodate oxidation of urothione and form B (dephospho) were prepared and purified by HPLC. The products differed irr their elution behavior in that the urothione product required 22 ml of 40% methanol, whereas the product from form B was eluted at 10 ml. In addition, the urothione periodate product, like its parent molecule, was nonfluorescent, whereas form B and its periodate product were intensely fluorescent. Nevertheless, additional evidence for the relatedness of urothione and form B can be adduced from the similarity of the absorption spectra of their periodate products (Fig. 5) .
The striking structural similarities between urothione and form B of the cofactor pterin suggested that urothione might in fact be the excretory product of the molybdenum cofactor. The ideal system for testing this hypothesis was fortunately available, in the form of urine samples from patients previously identified as deficient in active molybdenum cofactor (5) . These individuals show a combined deficiency of sulfite oxidase and xanthine dehydrogenase because of a lack of functional molybdenum cofactor and, as a result, show increased levels of sulfite and xanthine in plasma and urine and very low levels of uric acid. Analysis of liver samples obtained by biopsy or postmortem has shown that the liver tissue samples from patients lacked the specific pterin of the molybdenum cofactor, which was detectable in control liver samples by oxidative conversion to form A (manuscript in preparation). The amount ofurothione obtained from 1 liter ofcontrol urine (200 pg) coupled with the high sensitivity of HPLC for detection of UV-absorbing materials suggested that quantitation of this compound could be accomplished in a 10-ml sample ofurine simply by scaling down the purification procedure. Pooling of appropriate fractions eluted from QAE-Sephadex provided a level of urothione sufficient for UV detection on the HPLC, and its strong retention on the reverse-phase column aided in achieving resolution from other fluorescent and UV-absorbing species. Fig. 6 illustrates the HPLC elution profiles obtained from two samples of control urine and urine from five of the molybdenum cofactor-deficient patients. The urothione peak at 30 ml, easily detected in the control urine, was totally absent in the samples from the cofactor-deficient patients. The peaks at 28.5 ml in two of the patient samples (G and H) were not urothione, as verified by injection of a urothione standard with each sample (data not shown). Quantitation ofurothione by this procedure indicated an average value in adult controls of 143 pig/liter (n = 10; range = 38-273) and in children ranging in age from 3-5 yrs of 104 pkg/liter (n = 4; range = 42-221).
To further verify the absence of urothione in the urine of cofactor-deficient patients, samples pooled from QAE-Sephadex were boiled for 15 min with 5 mM KMnO4 in 0.1 M NaOH. Excess permanganate was destroyed, and the samples were cooled, centrifuged, and adjusted to pH 3.5 with HC1 for injection into the HPLC. The breakthrough fraction from several control samples was collected, and in each case its fluorescence spectrum was found to be identical to that of pterin-6-carboxylic-7-sulfonic acid. Even though conversion ofurothione to the sulfonic acid derivative is not quantitative, the yield of sulfonic acid in the control samples was proportional to the amount of urothione originally present in that sample. Significantly, no pterin-6-carboxylic-7-sulfonic acid was identified in samples from patients with molybdenum cofactor deficiency.~~~C 
DISCUSSION
The molybdenum cofactor in sulfite oxidase, xanthine dehydrogenase, and nitrate reductase can be oxidized in vitro to two fluorescent derivatives, form A and form B. Partial characterization of form A led to the conclusion that the native cofactor contains a reduced pterin ring system with a position-6 alkyl substituent and a terminal phosphate ester (2, 3) . Studies on the structure ofform B and its chemical and metabolic relationship to urothione provided corroborative evidence for the pterin nucleus in the active molybdenum cofactor. The presence of sulfur in the side chain is clearly established through the characterization of the form B permanganate product as pterin-6-carboxylic-7-sulfonic acid. The presence of a glycol function is evident from the periodate sensitivity of alkaline phosphatasetreated form B. The metabolic link between the molybdenum cofactor and urothione, indicated by the absence of urothione in urine from molybdenum cofactor-deficient patients, implies the presence of two sulfurs and at least four carbons in the side chain of the active cofactor.
The information summarized above may be assembled in a proposed model for active molybdenum cofactor as shown in Scheme H (top structure). In this scheme, the pterin nucleus Examination of form B by NMR and other techniques to be published elsewhere suggests that form B (dephospho) differs from urothione by the absence of the SCH3 function. Clearly ifform B retained the SCH3, such a function could be assigned to the native molecule. Its absence in form B leaves it unclear as to whether the sulfur, which is very likely to be present in the native cofactor, is methylated in the active molecule or is methylated in vivo only after release from a degraded molybdoenzyme as a signal for excretion.
Given the proposed structure for active molybdenum cofactor shown in Scheme II, a hypothetical pathway for conversion of active cofactor to urothione could be elaborated. According to this scheme, the molybdenum cofactor is freed ofits enzymic environment, loses molybdenum, and undergoes at least partial oxidation ofthe pyrazine ring. These steps allow afree SH group to attack the C-7 of the pterin with formation of the thiophene ring. Final modification for excretion would include dephosphorylation and perhaps (as discussed) methylation.
Although structural characterization of the active molybdenum cofactor remains incomplete, the basic chemical nature of an essential component (the pterin moiety) and its major functional groups -lave been identified through studies of inactive, oxidized degradation products. Final resolution ofthe structure will depend on more detailed analyses of these compounds as well as on isolation and characterization of the labile active cofactor itself.
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